Scholarlink

Background <p>Colorectal cancer (CRC) often evades immune surveillance, leading to poor responses to PD-1/PD-L1 blockade immunotherapy. The underlying mechanisms regulating PD-L1 expression remain incompletely understood.</p> Methods <p>We utilized co-immunoprecipitation (Co-IP) and RNA immunoprecipitation (RIP) to investigate protein-protein and protein–RNA interactions. Western blot (WB) and quantitative PCR (qPCR) were applied to assess protein and mRNA expression levels, respectively. Immunocompetent mouse models and patient-derived CRC samples were used to evaluate clinical relevance and therapeutic targeting.</p> Results <p>We identified acetylation of G3BP2 at lysine 76 (K76) as a key regulator of PD-L1-mediated immune evasion. This modification is catalyzed by p300 and reversed by HDAC6. Acetylated G3BP2 enhances binding to PABPC1 and PD-L1 mRNA, increasing its stability and upregulating PD-L1 expression. Consequently, tumors exhibit reduced cytotoxic T lymphocyte infiltration and acquire resistance to anti-PD-L1 therapy. Elevated G3BP2-K76 acetylation was observed in immunotherapy-resistant CRC tissues and promoted tumor growth in mice. A peptide inhibitor targeting K76 acetylation (K76-pe) effectively suppressed PD-L1 expression and synergized with anti-PD-L1 treatment in vivo.</p> Conclusion <p>G3BP2-K76 acetylation represents a critical post-translational mechanism driving immune evasion in CRC. Targeting this pathway may provide a promising strategy to overcome resistance to immunotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

G3BP2-K76 acetylation promotes tumor immunoescape by stabilizing PD-L1 expression in colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月30日

查看全文
  • Haiqing Jie,
  • Xuanhua Yang,
  • Yujie Hou,
  • Wenfeng Liang,
  • Wenxin Li,
  • Ze Li,
  • Dongxu Lei,
  • Hao Xie,
  • Tanxing Cai,
  • Zhiping Chen,
  • Yang Li,
  • Huashan Liu,
  • Liang Kang

摘要

Background

Colorectal cancer (CRC) often evades immune surveillance, leading to poor responses to PD-1/PD-L1 blockade immunotherapy. The underlying mechanisms regulating PD-L1 expression remain incompletely understood.

Methods

We utilized co-immunoprecipitation (Co-IP) and RNA immunoprecipitation (RIP) to investigate protein-protein and protein–RNA interactions. Western blot (WB) and quantitative PCR (qPCR) were applied to assess protein and mRNA expression levels, respectively. Immunocompetent mouse models and patient-derived CRC samples were used to evaluate clinical relevance and therapeutic targeting.

Results

We identified acetylation of G3BP2 at lysine 76 (K76) as a key regulator of PD-L1-mediated immune evasion. This modification is catalyzed by p300 and reversed by HDAC6. Acetylated G3BP2 enhances binding to PABPC1 and PD-L1 mRNA, increasing its stability and upregulating PD-L1 expression. Consequently, tumors exhibit reduced cytotoxic T lymphocyte infiltration and acquire resistance to anti-PD-L1 therapy. Elevated G3BP2-K76 acetylation was observed in immunotherapy-resistant CRC tissues and promoted tumor growth in mice. A peptide inhibitor targeting K76 acetylation (K76-pe) effectively suppressed PD-L1 expression and synergized with anti-PD-L1 treatment in vivo.

Conclusion

G3BP2-K76 acetylation represents a critical post-translational mechanism driving immune evasion in CRC. Targeting this pathway may provide a promising strategy to overcome resistance to immunotherapy.